Antigenic burden and serum IgG concentrations influence rituximab pharmacokinetics in rheumatoid arthritis patients.

about

Pharmacokinetics of rituximab and clinical outcomes in patients with anti-neutrophil cytoplasmic antibody associated vasculitis.Rituximab before and during pregnancy: A systematic review, and a case series in MS and NMOSD.

P2860

Q50014741-89C0592B-6BB1-4BA8-88A9-D52F919CB15F Q55442184-58BE93D8-064C-4C09-A5E5-FDB79959DC53

P2860

Antigenic burden and serum IgG concentrations influence rituximab pharmacokinetics in rheumatoid arthritis patients.

Item

http://www.wikidata.org/entity/Q38946557

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年学术文章

@wuu

2017年学术文章

@zh-cn

2017年学术文章

@zh-hans

2017年学术文章

@zh-my

2017年学术文章

@zh-sg

2017年學術文章

@yue

2017年學術文章

@zh

2017年學術文章

@zh-hant

name

Antigenic burden and serum IgG ...... rheumatoid arthritis patients.

@en

type

Item

label

Antigenic burden and serum IgG ...... rheumatoid arthritis patients.

@en

prefLabel

Antigenic burden and serum IgG ...... rheumatoid arthritis patients.

@en

P1476

Antigenic burden and serum IgG ...... rheumatoid arthritis patients

@en

P2093

Christophe Passot

http://www.w3.org/2001/XMLSchema#string

Céline Desvignes

http://www.w3.org/2001/XMLSchema#string

David Ternant

http://www.w3.org/2001/XMLSchema#string

Denis Mulleman

http://www.w3.org/2001/XMLSchema#string

Gilles Thibault

http://www.w3.org/2001/XMLSchema#string

Julien Mélet

http://www.w3.org/2001/XMLSchema#string

Soujanya Ratna Edupuganti

http://www.w3.org/2001/XMLSchema#string

Valérie Gouilleux-Gruart

http://www.w3.org/2001/XMLSchema#string

P2860

EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2013 update

The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands

The Concise Guide to PHARMACOLOGY 2015/16: Overview

Handling data below the limit of quantification in mixed effect models.

Evaluation of different tests based on observations for external model evaluation of population analyses.

IgG subclasses and allotypes: from structure to effector functions.

FcRn: the neonatal Fc receptor comes of age.

Repeated decrease of CD4+ T-cell counts in patients with rheumatoid arthritis over multiple cycles of rituximab treatment.

Population pharmacokinetic analysis of infliximab in patients with ulcerative colitis.

Target-mediated drug disposition model: approximations, identifiability of model parameters and applications to the population pharmacokinetic-pharmacodynamic modeling of biologics.

P304

1773-1781

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1111/BCP.13270

http://www.w3.org/2001/XMLSchema#string

P407

English

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Theodora Bejan-Angoulvant

Gilles Paintaud

Bertrand Lioger

P577

2017-04-12T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

28230269

http://www.w3.org/2001/XMLSchema#string

P932

5510084

http://www.w3.org/2001/XMLSchema#string

Antigenic burden and serum IgG concentrations influence rituximab pharmacokinetics in rheumatoid arthritis patients.

about

P2860

P2860

Antigenic burden and serum IgG concentrations influence rituximab pharmacokinetics in rheumatoid arthritis patients.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P407

P433

P478

P50

P577

P698

P932

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P407

P433

P478

P50

P577

P698

P932